Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions PTSD - Post Traumatic Stress Disorder
Phase PHASE3
Enrollment 1900
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of the REVEAL PTSD study is to test how well the Senseye DT works as a diagnostic test for Post-traumatic Stress Disorder (PTSD) in adults 18 and older who are experiencing one or more symptoms that might be related to PTSD. The Senseye DT is software as a medical device (SaMD) and is an iPhone app that administers a series of simple tasks on the phone while recording video during the tasks through the front-facing camera. The videos are analyzed by a an Artificial Intelligence (AI) algorithm to identify physiologic signals that might be indicative of PTSD. Data collected in this study will be used to train and tune the AI algorithm, then test it for accuracy. The main questions this study aims to answer are: 1. How accurate is the Senseye DT in detecting PTSD compared to structured clinical interviews, the current clinical standard for diagnostic testing? 2. How accurately does the Senseye DT predict PTSD severity? 3. How fast is the Senseye DT to use compared to structured clinical interviews? Participants will attend a virtual screening visit via video call to determine eligibility and consent to participate. Once enrolled, participants will attend 2 or 3 additional study visits: * Visit 1: A virtual visit where standard mental health assessments will be given by clinical raters trained in mental health and administering these structured clinical interviews. These assessments include the Structured Interview Guide for the Montgomery-Asburg Depression Rating Scale (SIGMA), the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A), and the MINI International Neurodiagnostic Interview. The Clinician-Administered PTSD Scale for DSM-5 Revised Version (CAPS-5-R) may also be conducted, if randomly selected. * Visit 2: A visit to use the Senseye DT. For participants near one of the study's physical site locations, this visit will be done in person at the site. For all others, this visit will be conducted virtually. * Visit 3: For participants not randomly selected to have the CAPS-5-R administered at Visit 1, a third and final visit will be scheduled for this assessment. This visit will be conducted virtually. The total expected participation time for enrolled participants is 6-7 hours over the course of 2-3 weeks.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Crossover Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: Senseye Diagnostic Tool (DT) — Software as a Medical Device - the Senseye DT is an investigational diagnostic device that is an application which can be installed on iPhones 13 and newer. The device administers various tasks on the phone screen that the participant completes while video and/or audio is recorded (depending on the task). Recordings are analyzed by a machine learning algorithm to predict the presence and severity of PTSD.
  • Behavioral: Clinician Administered PTSD Scale for DSM-5, Revised Version — The CAPS-5-R is a standardized stuctured clinical interview for determining PTSD presence and severity. It is a behavioral interview administered by a trained mental health clinician or clinical rater. Participant responses to various questions about traumatic experiences and resulting symptoms are scored to determine PTSD presence according to DSM-5 criteria and PTSD severity according to the CAPS-5-R severity scale.

Primary Outcomes

  • Sensitivity and Specificity of the Senseye DT as an objective PTSD diagnostic test (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-02-23
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1900 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Senseye, Inc.
Collaborators: Lindus Health, Medtryx Pty Ltd
Contact Information
Study Contact:
Priscilla Nechrebecki
(833) 459-9365
REVEALPTSD@lindushealth.com
Lily Berkowitz
lily.berkowitz@cuanschutz.edu
University of Colorado Anschutz Medical Campus
Steven Berkowitz, MD
University of Colorado Anschutz Medical Campus
Interventions
  • Device: Senseye Diagnostic Tool (DT) — Software as a Medical Device - the Senseye DT is an investigational diagnostic device that is an application which can be installed on iPhones 13 and newer. The device administers various tasks on the phone screen that the participant completes while video and/or audio is recorded (depending on the task). Recordings are analyzed by a machine learning algorithm to predict the presence and severity of PTSD.
  • Behavioral: Clinician Administered PTSD Scale for DSM-5, Revised Version — The CAPS-5-R is a standardized stuctured clinical interview for determining PTSD presence and severity. It is a behavioral interview administered by a trained mental health clinician or clinical rater. Participant responses to various questions about traumatic experiences and resulting symptoms are scored to determine PTSD presence according to DSM-5 criteria and PTSD severity according to the CAPS-5-R severity scale.
Study Locations (6 sites)
University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045 United States
Savannah VA Clinic, Savannah, Georgia 31419 United States
Velocity Clinical Research, Meridian, Idaho 83642 United States
Lindus Health (Virtual Study Site), Boston, Massachusetts 02111 United States
Lowcountry Center for Veterans Research, Charleston, South Carolina 29403 United States
Zenko Clinical Pty Ltd (Virtual Study Site), Carlton, Victoria 3053 Australia
Eligibility Criteria
Inclusion Criteria: 1. The participant is willing and able to read, understand, and sign the approved Informed Consent Form (ICF). 2. Age 18 years old or older. 3. In the past month, participant presents with at least one of the following: * nightmares or unwanted, intrusive thoughts * avoidance of specific thoughts or situations * feelings of being constantly on guard, watchful, or easily startled * feeling numb or detached from people, activities, or surroundings; and/or * persistent feelings of guilt or self blame for things that have happened. * excessive anxiety and worry (apprehensive expectation), occurring more days than not for at least 6 months, about a number of events or activities (such as work or school performance) * sleep disturbance (difficulty falling or staying asleep, or restless unsatisfying sleep) * depressed mood: most of the day, nearly every day, feeling sad, empty, or hopeless * markedly diminished interest or pleasure in activities: loss of interest or pleasure in most activities, nearly every day * self-report of significant weight loss or gain and/or changes in appetite * insomnia or hypersomnia: sleeping too little or too much * psychomotor agitation or retardation: observable restlessness or slowed movements * abnormal fatigue or loss of energy: feeling tired or lacking energy more than usual 4. Deemed likely to comply with the study protocol by the study team, including willing communication of adverse events (AEs), mental health history, current and past psychiatric medication \& treatments, and ability to attend all study visits. 5. Participant agrees to provide emergency contact information at Screening Visit and their physical location at each visit (if they are joining the visit remotely). 6. Participant is psychologically stable as determined by the investigator or delegate. 7. Participant has access to the following: * a device with stable internet and Wi-Fi connection capable of supporting video calls (e.g., tablet, computer with webcam, etc.) * a second smart device that must be an iPhone 13 or newer (Not inclusive of the iPhone13 Mini) 8. Participant home/environment meets criteria for Senseye DT setup (remote visits only) Exclusion Criteria: 1. Current diagnosis of epilepsy and/or other seizure disorders. 2. A history of at Screening OR positive at Visit 1 for bipolar I or II, mania, or one or more schizophrenia-spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, delusional disorder, psychotic depression, and psychosis. 3. Compromised facial neuro-ophthalmic integrity (e.g., due to stroke, MS, ALS, or other neurological conditions). 4. Current diagnosis of dementia, delirium, amnestic disorders, autism, hydrocephalus, posterior cortical atrophy, aphasia, multiple sclerosis, or stroke-related cognitive dysfunction. 5. Current eye disorders which prevent the patient from using the Senseye DT: * Vision impairment preventing ability to read with correction (including corneal disease, dense cataract, diabetic retinopathy, macular degeneration, glaucoma, etc.). * Use of corrective lenses including glasses and contacts is permitted. Colored contacts and cosmetic lenses that obscure or enhance the pupil are not permitted. * Significant eye lid droop blocking the pupil. * Persistent blurry vision, headaches, and/or light sensitivity resulting from conditions including abnormal pupil dilation or reactivity (e.g, mydriasis). * Recent eye surgeries (within 2 weeks) or planned eye surgeries within the study duration. * Intraocular inflammation, including iritis and anterior uveitis. * Ocular trauma resulting in uncorrected or permanent bilateral damage. 6. Active suicidal and/or homicidal intent or other self-injurious behavior which may put the participant and/or others at risk per the investigator's clinical judgement, or has suicidal ideation of level 4 or 5 as determined by the C-SSRS. 7. Suicidal behavior within the last year as determined by the C-SSRS at the time of screening. 8. Significant suicidal ideation within the last 6 months as determined by ideation of level 4 or 5 by the C-SSRS at the time of screening. 9. Current reported usage (within 2 weeks of Screening Visit and/or planned ongoing usage during the study) of psychotropic drugs and/or non-psychotropic drugs or medication which may affect use of the Senseye DT: * Narcotics/opioids (e.g., Heroin, Vicodin, oxycodone, codeine, Tramadol, etc.). * Tricyclic antidepressants (TCAs) (e.g., Tofranil, Pamelor, amitriptyline, doxeprin, etc.). * Monoamine Oxidase Inhibitors (MAOIs) (e.g., Emsam, Parnate, Nardil, Marplan, etc.). * Select antihypertensive medications (alpha-2 receptor agonists, clonidine, peripheral adrenergic inhibitors, Alpha \& Beta blockers, and Rauwolfia alkaloids). Note: If Prazosin can be abstained from for \> 24 hours prior to the Senseye DT visit, the exclusion does not apply for that medication. Stimulants (e.g., Amphetamines, Ritalin, Focalin, pseudoephedrine/Sudafed, ecstasy, cocaine, methamphetamines, cathinones, etc.). Note: Caffeine or nicotine use is not exclusionary. Note: that if Sudafed, pseudoephedrine, and stimulants commonly used to treat ADHD (e.g., Ritalin, Focalin, Adderall, etc. can be abstained from for \> 24 hours prior to the Senseye DT visit, the exclusion does not apply for those medications. * Psychedelics/psychotomimetics (Lysergic acid, psilocybin, mescaline, phencyclidine, methoxetamine, etc.). * Cholinergic or anticholinergic agents (e.g., Urecholine, Pilocar, Aricept, Miostat, Evoxac, ipratropium/Atrovent, oxybutynin/Ditropan, scopolamine, etc.), except antihistamines other than Benadryl or diphenhydramine. Note: If Benadryl/diphenhydramine can be abstained from for \> 24 hours prior to the Senseye DT visit, the exclusion does not apply. * Spravato or Ketamine. * Eye drops unless the participant is able to abstain from use for \> 72 hours prior to the Senseye DT visit. Note: Artificial tears can be used if needed during the Senseye DT use. * Central Nervous System (CNS) depressants (Benzodiazepines and Barbiturates) 10. Current reported usage (within 2 weeks of Screening Visit and/or planned ongoing usage during the study) of vagal nerve stimulation, deep brain stimulation, transcranial magnetic stimulation, or other stimulation or energy-based therapies. 11. Any condition which precludes the ability for patients to safely and accurately complete clinical assessments, questionnaires, or to follow instructions necessary to administer the Senseye DT (e.g., significant developmental disabilities, language disorders, cognitive deficiencies, or other neurodevelopmental disorders). 12. Medical diagnosis of Traumatic Brain Injury (TBI) within the last 12 months based on participant self-report. 13. Lifetime history of any of the following: surgical procedures involving the brain or meninges, encephalitis, meningitis, degenerative central nervous system (CNS) disorder (e.g., Alzheimer's Disease, Parkinson's Disease), or any other disease/procedure/accident/intervention that, according to the clinician, is deemed associated with significant injury to, or malfunction of, the CNS. 14. Involved in active litigation related to the participant's psychiatric symptoms 15. Pregnancy as determined by self-report. 16. Currently incarcerated. 17. Participant requires a legal authorized representative to consent. 18. Prior enrollment in this study or in other Senseye Machine Learning (ML) studies within the last 12 months. 19. Unwilling or unable to comply with all study related procedures, in the opinion of the investigator, including medical and non-medical procedures.
Conditions Diabetes (DM)
Phase Not Applicable
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The present study aims to compare the effects on glycated hemoglobin (HbA1c) at 3 months of two care models in patients with type 2 diabetes referred due to poor glycemic control: a day hospital endocrinology care model versus a care model centered on follow-up by a dietitian-nutritionist.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Other: Day Care Hospital — Clinical follow-up under the joint care of a nurse and an endocrinologist at Day Care Hospital
  • Other: Nutritionist — Clinical follow-up with a dietitian-nutritionist and an endocrinologist at ambulatory care unit

Primary Outcomes

  • Glycate hemoglobin (three months after completion of the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-30
Completion: 2026-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Consorci Sanitari de l'Alt Penedès i Garraf
Contact Information
Study Contact:
Noemí Casaponsa
+34 938960025
recerca@csapg.cat
Noemí Casaponsa
+34 938960025
recerca@csapg.cat
Hospital de Vilafranca
Altea Pérez
Hospital de Vilafranca
Interventions
  • Other: Day Care Hospital — Clinical follow-up under the joint care of a nurse and an endocrinologist at Day Care Hospital
  • Other: Nutritionist — Clinical follow-up with a dietitian-nutritionist and an endocrinologist at ambulatory care unit
Study Locations (1 sites)
Hospital de Vilafranca, Vilafranca del Penedès, Barcelona 08720 Spain
Eligibility Criteria
Inclusion Criteria: * Patients with a diagnosis of type 2 diabetes (T2DM) referred to endocrinology due to poor metabolic control. * Patients on insulin therapy Exclusion Criteria: * Referred from primary care for other reasons such as hypoglycemia. * Patients with other types of diabetes mellitus or with uncertainty in diagnostic classification. * Patients on rapid-acting insulin bolus therapy. * Patients with acute decompensation of diabetes. * Patients receiving corticosteroid treatment. * Dependent individuals for activities of daily living (ADL) with a Barthel index score below 60 or with cognitive impairment. * Language barrier.
Conditions Chronic Obstructive Pulmonary Disease, A...
Phase Not Applicable
Enrollment 470
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Chronic inflammatory pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD) and interstitial lung diseases (ILD) are characterised by lung inflammation and remodelling. Clinical, functional, microbiological, biological, pathological and prognostic features are highly variable and heterogeneous. Several phenotypes have been described within the same pathology, as similar phenotypic traits between different pathologies, or the coexistence of components of several diagnoses in the same patient, suggesting shared underlying mechanisms that could represent new therapeutic targets, beyond the initial medical diagnosis. The objectives of this prospective study are to analyze the phenotypic characteristics (clinical, demographic, biological, morphological, pathological, and microbiological characteristics) together with respiratory exposures and underlying mechanisms involving airway epithelium and inflammation processes in a cohort of patients diagnosed with asthma, COPD, bronchiectasis, CF, PCD and ILD.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Non applicable — Non applicable

Primary Outcomes

  • pheno-endotypes of inflammatory respiratory disease (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-15
Completion: 2040-09-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 470 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CHU de Reims
Contact Information
Study Contact:
Jeanne-Marie PEROTIN-COLLARD
03 10 73 67 63
jmperotin-collard@chu-reims.fr
Gaëtan DESLEE
03 26 78 76 11
gdeslee@chu-reims.fr
Damien JOLLY
326788472
djolly@chu-reims.fr
Chu Reims
Interventions
  • Other: Non applicable — Non applicable
Study Locations (1 sites)
Chu Reims, Reims, 51092 France
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Follow-up for one of the following conditions: asthma, COPD, bronchiectasis (DDB), cystic fibrosis (CF), primary ciliary dyskinesia (PCD), or interstitial lung diseases (ILD) * Healthy volunteers (controls) Exclusion Criteria: * Subjects protected by law (e.g., legal incapacity) * Any condition preventing informed consent or participation
Conditions Chronic Physical Health Conditions
Phase NA
Enrollment 260
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Chronic health conditions are common, disabling, and often co-occur with depression and anxiety. Internet-delivered cognitive behaviour therapy (ICBT) reduces barriers to treatment and has been adapted for chronic conditions. A transdiagnostic approach is promising because it is both effective and convenient in that clients with diverse conditions receive the same program. Both therapist-guided and self-guided formats have been found effective; however, in routine care therapist support is most common to ensure that clients have support to personalize care. This study evaluates the therapist-guided Chronic Conditions Course (CCC) and examines predictors of change. Past research shows that the most robust predictors of ICBT outcomes are baseline severity, adherence, credibility, and working alliance. However, few studies of ICBT for chronic conditions have examined predictors together. Moreover, the researchers are aware of no studies that have examined these core predictors in routine delivery of ICBT for those with chronic health conditions alongside other predictors-such as changes in thoughts and adaptive actions. A limitation of past work is that predictor analyses were typically secondary to trials designed for other purposes. This study directly addresses that gap by prospectively modeling predictors of change in routine care.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Internet-delivered CBT - Chronic Conditions Course (CCC) — The Wellbeing Course for Chronic Health Conditions is a transdiagnostic, internet-delivered cognitive behavioral intervention developed at Macquarie University. It is designed to help people living with chronic health conditions develop skills and strategies to maintain quality of life and emotional wellbeing. The course comprises 5 core online lessons released gradually over 8 weeks, targeting symptom identification, challenging unhelpful thoughts, pleasant activity scheduling, activity pacing and graded exposure, and relapse prevention. Each lesson is accompanied by downloadable exercise worksheets, case stories, and additional resources addressing challenges that clients may face alongside their chronic health conditions, such as assertive communication. Lesson materials are presented in a didactic, text-based format with visual supports. Therapists spend approximately 15 minutes each week responding to clients' messages and providing support.

Primary Outcomes

  • Depression (Baseline (Screening), weeks 1-8, and 20 from enrollment)
  • Anxiety (Baseline (Screening), weeks 1-8 and 20 from enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-08
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 260 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Regina
Collaborators: Macquarie University, Australia, Government of Saskatchewan, Ministry of Health
Principal Investigators:
  • Heather Hadjistavropoulos, PhD (PRINCIPAL_INVESTIGATOR) - University of Regina
Contact Information
Study Contact:
Marcie Nugent, MSW
306-337-3331
marcie.nugent@uregina.ca
Heather Hadjistavropoulos, PhD
306-585-5133
heather.hadjistavropoulos@uregina.ca
Marcie Nugent, MSW
306-337-3331
marcie.nugent@uregina.ca
Online Therapy Unit, University of Regina
Interventions
  • Behavioral: Internet-delivered CBT - Chronic Conditions Course (CCC) — The Wellbeing Course for Chronic Health Conditions is a transdiagnostic, internet-delivered cognitive behavioral intervention developed at Macquarie University. It is designed to help people living with chronic health conditions develop skills and strategies to maintain quality of life and emotional wellbeing. The course comprises 5 core online lessons released gradually over 8 weeks, targeting symptom identification, challenging unhelpful thoughts, pleasant activity scheduling, activity pacing and graded exposure, and relapse prevention. Each lesson is accompanied by downloadable exercise worksheets, case stories, and additional resources addressing challenges that clients may face alongside their chronic health conditions, such as assertive communication. Lesson materials are presented in a didactic, text-based format with visual supports. Therapists spend approximately 15 minutes each week responding to clients' messages and providing support.
Study Locations (2 sites)
Online Therapy Unit, University of Regina, Regina, Saskatchewan S4S 0A2 Canada
Online Therapy Unit, Regina, Saskatchewan S4S 0A2 Canada
Eligibility Criteria
Inclusion Criteria: * Saskatchewan resident (as funding is provided by Saskatchewan government); * Aged 18 years or older; * self-reported diagnosed with chronic physical health condition affecting mental health; * Access to a computer and the Internet; * Consent to treatment/research Exclusion Criteria: * Current severe psychiatric or medical condition that requires immediate treatment and or would interfere with participation (e.g. current mania or psychosis, actively suicidal or unable to keep themselves safe, medical condition requiring immediate surgery or other invasive treatment, cognitive difficulties); * Taking part in another treatment in our clinic; * Living outside of Saskatchewan
Conditions Preeclampsia
Phase NA
Enrollment 750
Locations 23 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study tests the hypothesis that, in women with preeclampsia without severe features, delivery management based on sFlt-1/PlGF would reduce the rate of induction of labor without worsening the rate of progression to preeclampsia with severe features and other maternal complications.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Intervention arm: expectant management if sFlt-1/PlGF<38 — If the angiogenic factors are normal (sFlt-1/PlGF \<38), expectant management will be followed until 39 weeks, instead of delivery at ≥37 weeks of gestation as in standard care for preeclampsia without severe features.
  • Other: Standard care: elective delivery at 37 weeks of gestation — In the control arm, standard care for preeclampsia without severe features will be followed: elective delivery at ≥37 weeks of gestation.

Primary Outcomes

  • Composite maternal outcome (through study completion, an average of 2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-04
Completion: 2028-04
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 750 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Collaborators: Instituto de Salud Carlos III
Contact Information
Study Contact:
Erika Bonacina, MD, PhD
003493 489 30 00
erika.bonacina@vallhebron.cat
Raquel Mula
+3493 227 47 47
raqmul@dexeus.com
Hospital Universitari Dexeus
Esther Canedo
+34981 178 000
esther_canedo@yahoo.es
Hospital Universitario de A Coruña
Interventions
  • Other: Intervention arm: expectant management if sFlt-1/PlGF<38 — If the angiogenic factors are normal (sFlt-1/PlGF \<38), expectant management will be followed until 39 weeks, instead of delivery at ≥37 weeks of gestation as in standard care for preeclampsia without severe features.
  • Other: Standard care: elective delivery at 37 weeks of gestation — In the control arm, standard care for preeclampsia without severe features will be followed: elective delivery at ≥37 weeks of gestation.
Study Locations (23 sites)
Hospital Universitari Dexeus, Barcelona, BARCELONA 08024 Spain
Hospital Universitario de A Coruña, A Coruña, Spain
Hospital General Universitari Dr. Balmis, Alicante, Spain
Vall d'Hebron Hospital Campus, Barcelona, Spain
Hospital Universitario de Cabueñes, Cabueñes, Spain
Hospital Universitario Puerta del Mar, Cadiz, Spain
Hospital General Universitario de Elche, Elche, Spain
Hospital Universitario de Getafe, Getafe, Spain
Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain
Hospital Universitario San Cecilio, Granada, Spain
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Singleton pregnancy * Preeclampsia without severe features according to the ACOG definition * Antegrade diastolic flow in the umbilical artery Doppler * Gestational age between 36+0 and 38+6 weeks of gestation * Gestational age confirmed by fetal crown-rump length measurement in the first-trimester scan (from 11+0 to 13+6 weeks of gestation) or by in vitro fertilization dates Exclusion Criteria: * Fetal death * Preeclampsia with severe features according to the ACOG definition, eclampsia, or any condition that requires immediate delivery * Absent or reversed end-diastolic flow in the umbilical artery Doppler * Non-reassuring CTG * Decreased fetal movements * Biophysical profile score ≤6 * Oligohydramnios * Refusal to provide informed consent * Fetal malformation * Placental abruption * Antiphospholipid antibody syndrome
Conditions T2DM (Type 2 Diabetes Mellitus)
Phase PHASE4
Enrollment 430
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Metformin — The dosage of metformin hydrochloride was consistent with baseline.
  • Drug: Triple Therapy of Other Oral Antidiabetic Drugs — The dosage of metformin hydrochloride was consistent with baseline. The usage and dosage of other hypoglycemic drugs were referred to their respective instructions.
  • Drug: ganagliflozin — Ganagliflozin tablet : 50mg/d.
  • Drug: liraglutide — Liraglutide injection: 0.6 mg/d for the first week, 1.2 mg/d for the second week, and 1.8 mg/d after the third week.

Primary Outcomes

  • The change of HbA1c compared to the baseline (from baseline to week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-03-29
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 430 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Xiaofen Qian
+86-0571-89908582
qianxiaofen@eastchinapharm.com
Wanting Zhang
+86-0571-89905517
zhangwanting@eastchinapharm.com
Ming Liu
+86 183 2201 7516
mingliu@tmu.edu.cn
Tianjin Medical University General Hospital
Interventions
  • Drug: Metformin — The dosage of metformin hydrochloride was consistent with baseline.
  • Drug: Triple Therapy of Other Oral Antidiabetic Drugs — The dosage of metformin hydrochloride was consistent with baseline. The usage and dosage of other hypoglycemic drugs were referred to their respective instructions.
  • Drug: ganagliflozin — Ganagliflozin tablet : 50mg/d.
  • Drug: liraglutide — Liraglutide injection: 0.6 mg/d for the first week, 1.2 mg/d for the second week, and 1.8 mg/d after the third week.
Study Locations (1 sites)
Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality China
Eligibility Criteria
Inclusion Criteria: * Meet the diagnostic criteria for type 2 diabetes (refer to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition)); -Age: 18-75 years old (including the threshold), male or female; * Body mass index (BMI) ≥20kg/m² ; * Patients who took 1000mg or more of metformin in combination with or without another oral hypoglycemic agent (except SGLT-2i and oral GLP-1RA) for at least 8 weeks before screening and had poor blood glucose control (centralized detection of HBA1C \>=7.5% and\<=11.0%); * Volunteer to participate in this study and sign informed consent. Exclusion Criteria: * Patients with type 1 diabetes or other special types of diabetes; * Patients with acute complications of ketoacidosis/hyperglycemic hyperosmolar state/lactic acidosis within 6 months before screening * Those who have used GLP-1RA and SGLT-2i drugs within 12 weeks before screening, or have used GLP-1RA and SGLT-2i drugs in the past and discontinued due to poor efficacy * Those who received insulin treatment within the previous week * Those who have a history of chronic or acute pancreatitis before screening, or have clinical manifestations of pancreatitis at the time of screening, or fasting triglycerides \> 5.7 mmol/L during the screening period * Liver function impairment at screening: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 UNL, or total blood bilirubin (TBIL) \> 2 UNL; * Renal impairment at screening: calculated according to the CKD-EPI formula, eGFR≤45 mL/min/1.73m² or serum creatinine≥1.5 UNL; * Patients with a past or family history of medullary thyroid cancer (MTC) and patients with multiple endocrine neoplasia syndrome type 2 (MEN2) * Female subjects who are currently pregnant, breastfeeding, or have a pregnancy plan during the study period * Those who have a history of hypersensitivity reaction to metformin, gapagliflozin, liraglutide injection and other drugs used in research and their excipients or have contraindications to the study drugs; * Those who have participated in other drug clinical trials within 3 months before screening; 21. Subjects who are unable to comply with the protocol under the judgment of the investigator, and those who have other serious physical or psychological diseases that may affect the effectiveness and safety.
Conditions Severe Asthma
Phase PHASE3
Enrollment 786
Locations 110 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. The study details include: Study treatment: randomized to receive either GB-0895 or placebo administered every 6 months over 52 weeks. Visit frequency: every 1-2 months after the first month.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: GB-0895 — Study Drug
  • Drug: Placebo — Placebo

Primary Outcomes

  • To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled asthma. (From Day 1 (randomization) to Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-12-03
Completion: 2028-12
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 786 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Generate Biomedicines
Principal Investigators:
  • Snodgres (STUDY_DIRECTOR) - Generate Biomedicines
Contact Information
Study Contact:
Generate Recruitment
888-469-0033
solairiastudy@generatebiomedicines.com
solairiastudy@generatebiomedicines.com
Research Site 23
solairiastudy@generatebiomedicines.com
Research Site 26
Interventions
  • Drug: GB-0895 — Study Drug
  • Drug: Placebo — Placebo
Study Locations (110 sites)
Research Site 23, Northridge, California 91324 United States
Research Site 26, Pasadena, California 91105 United States
Research Site 29, Rancho Cucamonga, California 91730 United States
Research Site 34, Valencia, California 91355 United States
Research Site 13, West Hills, California 91307 United States
Research Site 15, Colorado Springs, Colorado 80923 United States
Research Site 32, Brooksville, Florida 34613 United States
Research Site 12, Doral, Florida 33122 United States
Research Site 14, Gainesville, Florida 32607 United States
Research Site 03, Hialeah, Florida 33016 United States
Eligibility Criteria
1. Adults and adolescents ≥ 12 and ≤ 80 years of age. 2. Documented physician diagnosis of asthma for ≥ 2 years. 3. Subjects must be on medium to high dose ICS for ≥ 12 months before Screening Visit 1 plus at least 1 additional asthma controller (e.g., LABA, LAMA) ≥ 3 months before Screening Visit 1 with no change in ICS or controller(s) for at least three months. 4. Subjects must have a well-documented history of at least two asthma exacerbations requiring systemic corticosteroid treatment despite the use of medium-to-high dose ICS in the past 12 months before Screening Visit 1. 5. Adults ≥ 18 years of age at Screening Visit 1, a pre-BD FEV1 \<80% predicted at Screening Visit 1. 6. Adolescents 12 to \< 18 years of age at Screening Visit 1: A pre-BD FEV1 \< 90% predicted OR, FEV1:Forced Vital Capacity (FVC) ratio \< 0.80. 7. Positive BD responsiveness test: Increase of at least 12% and 200 mL in FEV1 between 15 and 60 minutes after the administration of a short-acting β2-agonist (SABA) at least once during the screening period. 8. ACQ-6 score ≥ 1.5 at the Screening Visit. 9. Weight ≥40 kg at the Screening Visit 1 Exclusion Criteria: 1. Subjects who experience a clinically significant asthma exacerbation within 12 weeks before the Screening Visit or during the run-in period and require a change in asthma maintenance therapy. 2. Other concurrent respiratory disease other than asthma, including (but not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, tuberculosis, diagnosis of chronic pulmonary disease (including but not limited to emphysema and/or chronic bronchitis), or a history of lung cancer. 3. Eosinophilic disease (e.g., eosinophilic granulomatosis with polyangiitis, eosinophilic esophagitis). 4. Any cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could affect subject safety, influence study findings or interpretation, or impede completion of the study. 5. Clinically significant infection that is unresolved and requires systemic antibiotic, antifungal, antiparasitic, or antiviral medications preceding enrollment. 6. A current malignancy or previous history of cancer within 5 years before screening. 7. Clinically significant infection that is not resolved before study enrollment. 8. Subjects with a known, pre-existing helminth parasitic infestation within 6 months before Screening Visit 1. 9. Current smokers or subjects with a smoking history ≥10 pack-years, and subjects using vaping products, including electronic cigarettes. 10. Former smokers with a smoking history of \<10 pack-years and users of vaping/e-cigarette products must have stopped for at least 6 months before Screening Visit 1 to be eligible. 11. Hepatitis B, C, or HIV. 12. Major surgery within 8 weeks before Screening Visit 1 or planned surgical procedures requiring general anesthesia or inpatient status for \>1 day during the study. 13. Use of any anti-IL-5 therapy (e.g., mepolizumab, reslizumab, benralizumab, depemokimab) within 12 months before Screening Visit 1 or other monoclonal antibodies used for asthma within 4 months or 5 half-lives. 14. Prior use (at any time) of any anti-TSLP or anti-TSLP receptor biologics, approved (e.g., tezepelumab) or investigational. 15. Treatment with systemic immunosuppressive/immunomodulating drugs (e.g., methotrexate, cyclosporine) within 12 weeks prior to randomization. 16. Receipt of an investigational biologic within 4 months or 5 half-lives, OR receipt of an investigational non-biologic within 30 days or 5 half-lives before Screening Visit 1. 17. Known history of sensitivity to any component of the study treatment formulation. 18. History of life-threatening anaphylaxis following any biologic therapy. 19. Concurrent enrollment in another clinical study involving investigational product (IP). 20. Subject has been randomized in the current study or previous GB-0895 studies. 21. Any clinically meaningful abnormal finding in physical examination, vital signs, ECG, hematology, serum chemistry, or urinalysis that, in the opinion of the Investigator, may put the subject at risk, influence study results, or impede study completion. 22. Cirrhosis (with or without hepatic dysfunction) or other active or clinically significant liver disease. 23. Receipt of immunoglobulin or blood products within 30 days before Screening Visit 1. 24. Receipt of live attenuated vaccines within 30 days before randomization and during the study, including the follow-up period. 25. Receipt of the T2 cytokine inhibitor suplatast tosilate within 15 days before Screening Visit 1. 26. Subjects treated with bronchial thermoplasty in the last 12 months before Screening Visit 1. 27. Unwillingness or inability to follow study procedures, including poor adherence to asthma controller medications, in the opinion of the Investigator. 28. Women who are pregnant, lactating, or planning to become pregnant during the study. 29. History (or suspected history) of alcohol misuse or substance abuse within 2 years before Screening Visit 1.
Conditions Pulmonary Hypertension, Systemic Scleros...
Phase Not Applicable
Enrollment 350
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Pulmonary Arterial Hypertension (PAH) is a rare and severe condition that can be associated with Systemic Sclerosis (SSc), significantly worsening the prognosis of the latter disease. Screening programs based on clinical, laboratory, pulmonary function test, electrocardiographic, and echocardiographic data have been shown to enable earlier diagnosis and improve the prognosis of PAH associated with SSc. However, the hemodynamic criteria for the diagnosis of PAH have recently changed, and the usefulness of these screening programs in this new context is unknown. The primary objective of this study is to develop a PAH screening program in patients with SSc through the use of different artificial intelligence algorithms, comparing these algorithms with classical screening programs. These algorithms will be externally validated in different hospitals in Spain. As secondary objectives, the study will assess the usefulness of various proteins involved in the metabolic pathways related to the development of PAH, as well as certain parameters of right ventricular function and measures of quality-of-life impact, in the prognostic evaluation of PAH associated with SSc. To this end, simple and reproducible clinical data will be used, such as electrocardiogram, echocardiogram, and different quality-of-life scales obtained from major PAH and SSc registries. Machine learning techniques and Bayesian networks will be applied to generate artificial intelligence models for screening and prognostic assessment.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • Diagnostic accuracy of AI-based screening models for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) (At baseline (cross-sectional assessment at study entry))
  • Event-free survival in patients with systemic sclerosis-associated PAH (Up to 24 months of follow-up)
  • Patient-reported quality of life in systemic sclerosis-associated PAH (Baseline and 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-30
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alejandro Cruz Utrilla
Contact Information
Study Contact:
Marta Garcia Morales Department of Respiratory Medicine
958023000
info@ibsgranada.es
Hospital Universitario Clínico San Cecilio
Amaya Martínez Meñaca Department of Respiratory Medicine
942202520
amaya.martinez@scsalud.es
Hospital Universitario Marqués de Valdecilla
Manuel López Meseguer Department of Respiratory Medicine
934893000
manuel.lopez@vallhebron.cat
Hospital Universitario Vall d'Hebron
Interventions
N/A
Study Locations (5 sites)
Hospital Universitario Clínico San Cecilio, Granada, Andalusia 18007 Spain
Hospital Universitario Marqués de Valdecilla, Santander, Cantabria 39008 Spain
Hospital Universitario Vall d'Hebron, Barcelona, Catalonia 08035 Spain
Hospital Universitario Ramón y Cajal, Madrid, Madrid 28034 Spain
Hospital Universitario 12 de Octubre, Madrid, Madrid 28041 Spain
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Clinical diagnosis of systemic sclerosis (SSc) according to ACR/EULAR criteria * For controls (SSc without PAH): absence of pulmonary arterial hypertension; patients with isolated or combined post-capillary pulmonary hypertension (pulmonary capillary pressure \> 15 mmHg) or Group 3 pulmonary hypertension may be included, limited to 20% of this group * For cases (SSc-associated PAH): confirmed PAH by right heart catheterization (mean pulmonary arterial pressure \> 20 mmHg, pulmonary capillary pressure \< 15 mmHg, pulmonary vascular resistance \> 2 Wood Units) Exclusion Criteria: * Missing data in the main variables at diagnosis (clinical assessment, blood tests, electrocardiogram, transthoracic echocardiogram). * Inability to provide informed consent

Patients With Type 2 Diabetes

NCT07245082
Recruiting
Conditions Diabetes Mellitus Type 2
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Diabetes mellitus

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Changes in nutritional status and physical function (including dietary habits, body composition, and grip strength) (Everytime after physician's appointment(Usually 3 months).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-09
Completion: 2028-08-21
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Principal Investigators:
  • Chia-Wen Lu, Present Professor (STUDY_CHAIR) - Department of Family Medicine, National Taiwan University Hospital
Contact Information
Study Contact:
Chia-Wen Lu, Present Professor
886-2-23123456
biopsycosocial@gmail.com
Interventions
N/A
Study Locations (1 sites)
National Taiwan University Hospital, Taipei, Zhongzheng Dist 100229 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 18 or older. 2. Patients diagnosed with type 2 diabetes (based on medical history, diagnostic code, or use of hypoglycemic medication). 3. Participants are willing to participate in the study and have signed the consent form. 4. Participants are able to complete basic assessments (e.g., height, weight, waist circumference, grip strength, body composition, etc.). Exclusion Criteria: 1. Individuals who cannot understand the study content. 2. Individuals who cannot cooperate with relevant assessments. 3. Other individuals who are clinically deemed unsuitable for participation by the project leader.
Conditions Pain, Depressive Symptoms, Aging
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Older adults who are 50 years of age and older with depressive symptoms, pain and difficulty with mobility will participate in the SPARK intervention study that includes 8 nurse visits in participants' homes to help participants with participants' pain and mood.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: SPARK — The SPARK program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.

Primary Outcomes

  • Change in Pain Intensity as assessed by the Patient Reported Outcomes Measurement Information System (PROMIS) (Baseline, 12 weeks and 24 weeks)
  • Change in Pain Interference as assessed by the PROMIS Pain Interference (Baseline, 12 weeks and 24 weeks)
  • Change in Depressive Symptoms as assessed by the Patient Health Questionnaire 9 (PHQ-9) (Baseline, 12 weeks and 24 weeks)
  • Change in Depressive Symptoms as assessed by the PROMIS 57 (Baseline, 12 weeks and 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2028-11-30
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Principal Investigators:
  • Janiece L Taylor, PhD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins School of Nursing
  • Meagan Clemence, MA (STUDY_DIRECTOR) - Johns Hopkins University
Contact Information
Study Contact:
Janiece Taylor, PhD
443-287-4503
jwalke90@jhu.edu
Meagan Clemence, MS
mcleme26@jh.edu
Janiece Taylor, PhD
443-287-4503
jwalke90@jhu.edu
Johns Hopkins School of Nursing
Interventions
  • Behavioral: SPARK — The SPARK program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.
Study Locations (1 sites)
Johns Hopkins School of Nursing, Baltimore, Maryland 21205 United States
Eligibility Criteria
Inclusion Criteria: * Self-report pain \>3 out of a 0 -10 scale that has lasted longer than 3 months and keeps subjects from doing at least one activity that subjects would like to do * Live in the community * Live in Central Maryland * Score a 5 or higher on the PHQ-9 (depression measure) at least two times during a two week period (screening call and then at first data collection visit) * Must be pre-frail (one or two criteria on frailty phenotype) or frail (three or more of the criteria on frailty phenotype) * One ADL or IADL limitation Exclusion Criteria: * Hospitalized \> 3 times in the last year * Participating in physical therapy * Have a terminal diagnosis (\<1 year expected survival) * \> moderate intellectual impairment (5-7 errors) based on the Short Portable Mental Status Questionnaire (SPMSQ) * Unable to speak or understand English
Conditions Cirrhoses, Liver
Phase PHASE2
Enrollment 154
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if the medicine vonoprazan can help prevent ulcers that may develop after endoscopic variceal band ligation (EVBL) in adults with liver cirrhosis. These ulcers sometimes cause pain or delayed bleeding after the procedure. The study will also look at how well vonoprazan is tolerated and if it improves comfort after the procedure. The main questions this study will answer are: Does vonoprazan lower the number and severity of ulcers found on endoscopy after EVBL? Does vonoprazan reduce swallowing pain or chest discomfort compared with placebo? Is vonoprazan safe and well tolerated in people with liver cirrhosis? Researchers will compare vonoprazan 20 mg once daily with a placebo (a look-alike tablet that contains no active medicine) to see if vonoprazan works better to prevent these ulcers. Participants will: Take vonoprazan or placebo by mouth once daily for 14 days after EVBL. Return for a follow-up endoscopy about two weeks later to check for ulcers. Report any symptoms such as pain, nausea, or swallowing difficulty during the study. Adults aged 18 to 75 years with liver cirrhosis who undergo EVBL will be invited to join. Participants will be randomly assigned to one of two groups, and neither they nor the study doctors will know which treatment they receive (double-blind design). The study will take place at Mayo Hospital, Lahore, Pakistan, over about six months. By comparing vonoprazan to placebo, researchers hope to find a better way to protect the esophagus and stomach after EVBL, reduce post-procedure pain, and support faster recovery in people with liver cirrhosis.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Drug: Vonoprazan 20 mg — Vonoprazan is a potassium-competitive acid blocker (P-CAB) that provides strong and sustained suppression of gastric acid secretion. In this study, participants will receive vonoprazan 20 mg by mouth once daily for 14 days after endoscopic variceal band ligation (EVBL). The tablets will be taken with water, preferably before breakfast. This dose and duration are based on prior clinical experience in acid-related disorders. The aim is to determine whether vonoprazan prevents the formation of ulcers and reduces post-procedure pain compared with placebo.
  • Other: Placebo — Participants in the placebo group will receive a look-alike oral tablet with no active medicine, once daily for 14 days after EVBL. The placebo will be identical in color, size, and packaging to the Vonoprazan tablet to maintain blinding. This comparator will help determine whether Vonoprazan provides any true benefit in preventing ulcers and improving symptoms beyond standard post-procedure care.

Primary Outcomes

  • Incidence of Post-Endoscopic Variceal Band Ligation (EVBL) Ulcers (At follow-up endoscopy, 14 ± 1 days after EVBL.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-12-16
Completion: 2026-03-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 154 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: King Edward Medical University
Contact Information
Study Contact:
Muhammad R Tariq, MBBS,FCPS
+923337692728
ibneislam190@gmail.com
Muhammad Sheikh
03219994005
dr.usheikh@gmail.com
King Edward Medical University/Mayo Hospital
Interventions
  • Drug: Vonoprazan 20 mg — Vonoprazan is a potassium-competitive acid blocker (P-CAB) that provides strong and sustained suppression of gastric acid secretion. In this study, participants will receive vonoprazan 20 mg by mouth once daily for 14 days after endoscopic variceal band ligation (EVBL). The tablets will be taken with water, preferably before breakfast. This dose and duration are based on prior clinical experience in acid-related disorders. The aim is to determine whether vonoprazan prevents the formation of ulcers and reduces post-procedure pain compared with placebo.
  • Other: Placebo — Participants in the placebo group will receive a look-alike oral tablet with no active medicine, once daily for 14 days after EVBL. The placebo will be identical in color, size, and packaging to the Vonoprazan tablet to maintain blinding. This comparator will help determine whether Vonoprazan provides any true benefit in preventing ulcers and improving symptoms beyond standard post-procedure care.
Study Locations (1 sites)
King Edward Medical University/Mayo Hospital, Lahore, Punjab Province 54000 Pakistan
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 75 years (male or female) * Diagnosis of liver cirrhosis confirmed by clinical, biochemical, or imaging findings. * Presence of documented esophageal varices requiring endoscopic variceal band ligation (EVBL). * Able and willing to provide written informed consent in English or Urdu. * Willing to comply with study procedures, including taking study medication and attending follow-up endoscopy. Exclusion Criteria: * History of gastric or esophageal surgery * Allergy or contraindication to vonoprazan or study drug components * Pregnant or lactating women * Individuals who are non-cooperative or unable to understand local languages * Critically ill patients, including: ICU admission Requirement for mechanical ventilation GCS \< 10 * Active gastrointestinal bleeding at the time of enrollment * Malignancy of the upper gastrointestinal tract
Conditions Asthma, COPD
Phase Not Applicable
Enrollment 600
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Current diagnostic methods for asthma and chronic obstructive pulmonary disease mostly depend on pulmonary function tests, especially spirometry. While spirometry is a foundational tool, its diagnostic accuracy is often limited by the patient's ability to perform forceful breathing maneuvers, as well as technical and reproducibility challenges, and the need for proper equipment and training. These constraints can compromise effective diagnosis of asthma and COPD in primary care settings. Prompt and accurate diagnosis by primary care physicians is essential for better patient outcomes. Although variable airflow limitation often measured as a change in FEV1 after bronchodilator is a hallmark of asthma, inconsistencies in test quality and reversibility criteria create challenges in distinguishing asthma from COPD. These complexities highlight the need for alternative diagnostic tools beyond traditional spirometry. This observational study is designed to evaluate the diagnostic accuracy and technical feasibility of using oscillometry and FeNO testing in primary care for suspected asthma and COPD, compared to conventional specialist-based diagnostics. The study will be conducted across 7 countries in the MEA, Asia, and Latin America, with two hospital sites per country. Primary care physicians will be trained in oscillometry and FeNO testing using standardized protocols and tools such as the Ambulatory Lung Diagnosis System following GINA and GOLD guidelines. Eligible patients will provide consent, complete a history and symptom questionnaire, and undergo primary care-based assessment for a provisional diagnosis. If specialist assessment cannot occur the same day, it will be done within three days. No follow-up visits are planned. Study outcomes will inform the feasibility and accuracy of integrating these methods into routine care, aiming to improve the early and reliable diagnosis of asthma and COPD.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Accuracy of primary care asthma/COPD diagnosis using oscillometry (ALDS: R5, R20, R5-R20, X5, Ax) plus FeNO ≥50 ppb (Fenom PRO®/ALDS Pro) vs specialist gold standard; metrics: Cohen's kappa, agreement, sensitivity, specificity in overall, asthma, COPD (1 to 3 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-26
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
N/A
Study Locations (12 sites)
Research Site, Buenos Aires, Argentina
Research Site, Medoza, Argentina
Research Site, Alexandria, Egypt
Research Site, El Waili, Egypt
Research Site, Monterrey, Mexico
Research Site, Santiago de Quer Taro, Mexico
Research Site, Riyadh, Saudi Arabia
Research Site, Taichung, Taiwan
Research Site, Taoyuan City, Taiwan
Research Site, Dubai, United Arab Emirates
Eligibility Criteria
Inclusion Criteria: Patients are eligible to be included in the study if all the following criteria apply and after providing written informed consent: Suspected asthma (asthma group) 1. Patients ≥ 18 years old or with legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the ICF. 2. Patients presenting with symptoms of wheezing, cough, chest tightness, shortness of breath, but without a clinically confirmed diagnosis of asthma. Suspected COPD (COPD group) 1. Patients ≥ 40 years old at the time of signing the ICF. 2. Patients presenting with symptoms of dyspnea, chronic cough or sputum production, but without a clinically confirmed diagnosis of COPD. Exclusion Criteria: Patients are excluded from the study if any of the following criteria apply: 1. Prior diagnosis of COPD or asthma. 2. Use of ICS in the last 6 months or use of oral corticosteroids in the last 3 months. 3. Any diseases that influence lung function result such as lung cancer, pneumonia, active pulmonary tuberculosis, pulmonary embolism, and interstitial lung disease. 4. Any history of recent surgery that affects lung function results, including but not limited to thoracotomy surgery, pneumothorax surgery, and thoracic drainage. 5. Contraindication to spirometry or oscillometry test, or allergy to bronchodilator. 6. Currently pregnant or breast-feeding women. 7. If the investigator judges that the patient is unlikely to comply with study procedures, restrictions, and requirements.